People on the Move - PharmaLive

Biopharma/Biotech

Photo: F. Wiklund

Fredrik Wiklund has been made chief operating officer of Bioniz Therapeutics Inc. As a key member of the executive leadership team, Mr. Wiklund will be responsible for leading the company’s business, operations, strategy, corporate development, finance, commercial planning, investor relations and corporate communications. He joins Bioniz from Celladon Corp. where he served as VP, corporate development and investor relations. He also served as president and CEO as the company merged with Eiger Biopharmaceuticals.

Matthew Moyle, Ph.D., is now chief scientific officer of AnaptysBio Inc. Dr. Moyle will be responsible for the discovery and early development of therapeutic antibodies generated using AnaptysBio’s proprietary SHM-XEL platform. Most recently, Dr. Moyle served as VP of Biotherapeutics at Boehringer Ingelheim Pharmaceuticals Inc. where he chaired Boehringer Ingelheim’s International NBE Council. He earned a Ph.D. and B.Sc. in Biochemistry at the University of Toronto.

Dr. Alfredo Zuro was appointed chief medical officer of Glycotope GmbH. His last role was at Mologen AG, where he was chief medical officer and a member of the executive board.

Paul Sauer is now VP, Process Development and Manufacturing, at SutroVax. He was VP of Process Sciences & Manufacturing at Igenica Biotherapeutics, where he initiated the company’s development activities and built its supply chain network for GMP manufacturing of its antibody drug conjugates.

Photo: J. McKew

John C. McKew, Ph.D., has joined Lumos Pharma Inc. as its chief scientific officer. Dr. McKew most recently served as VP of Research for aTyr Pharma.

Beth Eastland has become VP of sales of Orexigen Therapeutics Inc. Eastland was at Merck & Co. Inc. from 1989 through 2015, where she held roles of increasing responsibility in the United States Human Health Division, leading sales teams for primary care, specialty and hospital products and multiple product launches. Additionally, Dr. Preston Klassen has resigned to pursue other interests in drug development with a private company. Peter Flynn, Ph.D., has been appointed as senior VP, head of Development, Regulatory Affairs, and Safety. Toni Foster will continue in her role as senior VP, Project Management Office and Clinical Operations. Orexigen is a biopharmaceutical company focused on the treatment of obesity.

Pnina Strauss-Levy is now VP, Clinical and Regulatory Affairs, at Intec Pharma Ltd. Strauss-Levy has served in several positions with Kamada Ltd., including as VP, Clinical Development & IP. Intec Pharma is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology.

Specialty Pharma

John T. Hendrickson has become CEO of Perrigo Co. following the resignation and departure of Joseph C. Papa. Hendrickson has served as president of Perrigo since October 2015. He was formerly executive VP, Global Operations & Supply Chain between 2007 and 2015 and has held numerous other management and operational leadership roles at Perrigo since he joined the company in 1989, including leading the U.S. Consumer Healthcare business from 2003 to 2007. Papa resigned in April and will not be standing for re-election at the company’s 2016 general annual meeting of shareholders.

Harold A. Deas Jr. is now CEO of Avion Pharmaceuticals LLC. Deas will retain his role as chief operating officer. Daily commercial operations and management will continue to be led by Michael E. Sullivan, president of Avion. Avion Pharmaceuticals develops and markets a portfolio of innovative pharmaceutical products in the women’s heath and dermatology therapeutic areas.

Kathleen Gogas, Ph.D., is appointed VP of preclinical development at Symic. Dr. Gogas will lead the company’s research efforts in preclinical pharmacology and oversee IND enabling research. Prior to joining Symic, Dr. Gogas was senior director of preclinical pharmacology at Nektar Therapeutics. Symic is a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function.

James Pekarsky has resigned as chairman, CEO, and treasurer of BioPharmX Corp. President, Co-Founder and Director Anja Krammer continues to manage the company, a role she has played since BioPharmX was established. Greg Kitchener, chief financial officer, assumed the responsibilities of treasurer.
BioPharmaX is a specialty pharmaceutical company developing products for the dermatology and women’s health markets.

Sharon Clarke is now chief commercial officer of Tris Pharma Inc. Clarke will lead Tris’ brand business and launch its first commercial product. Clarke was most recently head of commercial operations of Kaleo Inc. Tris Pharma is a specialty pharmaceutical company focused on the research and development of innovative, technologies-driven products, pioneering the delivery of controlled release in the liquid, chewable/ODT, and strip dosage forms so patients do not have to swallow a pill.

Stephen P. Carey was made VP and chief financial officer of ANI Pharmaceuticals Inc. Carey has held various financial and accounting positions with Schering-Plough Corp. and most recently, Par Pharmaceutical Companies Inc., where he was the senior VP, controller and principal accounting officer. Carey replaces Charlotte C. Arnold, who will remain as a consultant to the company through March 2017. ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Deb Mathews, Pharm.D., has joined Synthetic Biologics Inc. in the new position of VP, medical affairs. Dr. Mathews will be responsible for all medical affairs-related activities, with a focus on supporting late-stage clinical development for the company’s two lead GI microbiome-focused drug candidates. Most recently Dr. Mathews served as executive medical science lead at Bayer HealthCare Pharmaceuticals Inc. Synthetic Biologics is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases.

Service Companies

Photo: J. Nolan

Joe Nolan has become president of Dohmen Life Science Services (DLSS). Nolan joins DLSS with more than 30 years of experience in the pharmaceutical industry, most recently serving as chief commercial officer and senior VP of Marathon Pharmaceuticals. Nolan will oversee Dohmen’s DLSS division, a one-stop-shop for drug and device companies to access capability ranging from compliance services, channel supply support, revenue cycle management and direct to patient care. Dohmen Life Science Services provides intelligent outsourcing to biopharma and medical device companies.

Dr. Louis Yu was tapped to fill the newly created position of senior VP of quality and compliance at Albany Molecular Research Inc. (AMRI). Dr. Yu will report to William S. Marth, AMRI’s president and CEO. Dr. Yu will oversee all aspects of quality and cGMP compliance at all divisions of AMRI, including Drug Discovery Services, API, and Drug Product development and manufacturing. Most recently, he served as executive VP, global quality & compliance for Perrigo. AMRI is a global contract research and manufacturing organization.